Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

ing innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.

Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Applications for approval of INTELENCE have also been submitted to the European Agency for the Evaluation of Medicinal Products (EMEA) and with regulatory authorities in Canada, Switzerland, Russia and Australia.

Ortho Biotech Products, L.P. and Tibotec Pharmaceuticals Ltd. are subsidiaries of Johnson & Johnson.

Forward-Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Tibotec Pharmaceuticals Ltd.'s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available onl
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCa...PHM ) today announced that it will release its fin...ar 2010 on December 10, 2009 at 7:00 a.m. EST and ... the results at 11:30 a.m. EST on the same day. ,...ancial results for the second quarter ended Octobe...
(Date:12/2/2009)... , COLUMBIA, Md., Dec. 2 /PRNewswire-FirstCall/...) announced today that it intends to release the r...on December 16, 2009, at approximately 4:00 p.m. E...p.m. ET Martek will conduct a conference call to d...ed parties may listen to the call live via webcast...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Reportl...ort is available in its catalogue: ,, Drug Dis...ends & Opportunities ,, http://www.report...A-Global-Update-of-Market-Trends--Opportunities.ht...d ongoing element of every pharmaceutical company,...
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCall/ ...mpany") (TSX:ONC; NASDAQ: ONCY ) announced today t...it offering, the underwriters have exercised in fu...ditional 637,500 units. Each unit is comprised of ...e warrant, and was sold at a price of US$3.00 per ...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4
...UT HILL, MA (February 24, 2009) An engineered met...-art device in the complex terahertz range of the ...rformance for modulating tiny waves of radiation, ...lege, the Los Alamos and Sandia national laborato...ent applied to the metamaterial a hybrid structur...
...lity and Plug and Play Capability of MyMedicalReco...hcare Technology Experts Expected at HIMSS09 , , .... (OTC Bulletin Board: FVRL), which through its wh... Inc. (collectively, "MMR") provides consumer-cont...dicalrecords.com ) and electronic safe deposit box...
...IS, January 24 The European Commission has grante...) /Thymanax(R) (agomelatine),the first melatonergi...ts,with major depressive episodes. , "There is... the,devastating effects of depression," said Prof...ted Kingdom. "Valdoxan is an innovative, new appro...
Other Biology Technology:Team develops new metamaterial device 2Team develops new metamaterial device 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 2MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 4MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 5Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 2Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 3
(Date:12/4/2009)... the total gene activity in organs relevant for co...dish medical university Karolinska Institutet have...r the recruitment of white blood cells into the at...e published in the open-access journal PLoS Genet...e blood cells in the development of atherosclerosi...
(Date:12/4/2009)...ncephalogram (EEG) is widely used by physicians an...se neurological disorders. However, it has remaine...ad give an exact view of what is happening inside ...for Biological Cybernetics in Tbingen, Germany, ha...enerated within the brain to that measured with EE...
(Date:12/4/2009)...mathematical model of heart cells, University of I...ritical enzyme, calmodulin kinase II (CaM kinase),... , The study, which also involved Columbia Univ... PLoS Computational Biology . , "Recently, res...in kinase II as a critical regulator of the heart,...
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How to read brain activity? 2U-Iowa study helps advance heart-related research 2Publicis Groupe Second Group Most Awarded in Cannes With a Total of 101 Lions 50379 1Publicis Groupe Second Group Most Awarded in Cannes With a Total of 101 Lions 50379 2Nebraska Prescription Assistance Program Launched 50377 1Nebraska Prescription Assistance Program Launched 50377 2PROLOR Biotech Awarded Two U S Patents for Its Longer Acting Human Growth Hormone and Longer Acting Erythropoietin 12845 1PROLOR Biotech Awarded Two U S Patents for Its Longer Acting Human Growth Hormone and Longer Acting Erythropoietin 12845 2PROLOR Biotech Awarded Two U S Patents for Its Longer Acting Human Growth Hormone and Longer Acting Erythropoietin 12845 3
...ame back after treatment had almost twice as much ...d cancer-free despite treatment with anti-estroge...searchers in a study published in the March issue ... a journal of the American Association for Cancer ...s of estrogen contribute to an increased risk of c...
...estral toehold on dry land with considerable help ...hat partnership is being exploited as a strategy t...iofuels. The genetic mechanism of this kind of sym...al balance in healthy forests, also provides insig...nt carbon sequestration and enhanced phytoremediat...
...-- Cell Press has been chosen by The Biophysical S... from January 2009. The Biophysical Society and C...Biophysical Journal content and that of the Cell P...ell, Current Biology, and Structure. , For more th...he development and publication of knowledge in bio...
Other Biology News:High levels of estrogen associated with breast cancer recurrence 2Mechanisms of plant-fungi symbiosis characterized by DOE Joint Genome Institute 2Mechanisms of plant-fungi symbiosis characterized by DOE Joint Genome Institute 3Mechanisms of plant-fungi symbiosis characterized by DOE Joint Genome Institute 4Cell Press announces new partnership with the Biophysical Society 2
SV40 Large T Antigen from Chimerx
NuParaffin Kit from Exalpha Biologicals, Inc.
ChemiArray Mouse Lysate Cytokine Antibody Array III, 62 cytokines per membrane from CHEMICON
Universal Amplification Primer from Invitrogen
Biology Products: